Published in J Med Chem on August 01, 1991
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest (1997) 1.83
Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir Res (2008) 1.56
Carboxylic acid (bio)isosteres in drug design. ChemMedChem (2013) 0.97
Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci U S A (1994) 0.88
α-Amino Acid-Isosteric α-Amino Tetrazoles. Chemistry (2016) 0.77
Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem (2010) 0.77
Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands. ACS Med Chem Lett (2014) 0.75
Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists. Bioorg Med Chem (2008) 0.75
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. Pain (2016) 0.75
A short and efficient synthesis of valsartan via a Negishi reaction. Beilstein J Org Chem (2010) 0.75
Synthesis of Novel 1,4- Dihydropyridine Derivatives Bearing Biphenyl-2'-Tetrazole Substitution as Potential Dual Angiotensin II Receptors and Calcium Channel Blockers. Adv Pharm Bull (2011) 0.75
Comparisons of pKa and log P values of some carboxylic and phosphonic acids: synthesis and measurement. AAPS PharmSci (2001) 0.75
Improved synthesis of 5-substituted 1H-tetrazoles via the [3+2] cycloaddition of nitriles and sodium azide catalyzed by silica sulfuric acid. Int J Mol Sci (2012) 0.75
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet (2011) 10.73
Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med (1978) 9.29
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev (1993) 4.69
Anomalous origin of the left coronary artery from the pulmonary trunk. Its clinical spectrum, pathology, and pathophysiology, based on a review of 140 cases with seven further cases. Circulation (1968) 4.34
Mortality from epilepsy: results from a prospective population-based study. Lancet (1994) 4.31
Control of DNA synthesis genes in fission yeast by the cell-cycle gene cdc10+. Nature (1992) 4.13
Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J (1993) 3.57
Coordination of expression of DNA synthesis genes in budding yeast by a cell-cycle regulated trans factor. Nature (1991) 3.53
Coordinated regulation of gene expression by the cell cycle transcription factor Swi4 and the protein kinase C MAP kinase pathway for yeast cell integrity. EMBO J (1996) 3.45
A multicopy suppressor gene of the Saccharomyces cerevisiae G1 cell cycle mutant gene dbf4 encodes a protein kinase and is identified as CDC5. Mol Cell Biol (1993) 3.33
SWI6 protein is required for transcription of the periodically expressed DNA synthesis genes in budding yeast. Nature (1992) 3.32
Effect of Aluminum Hydroxide Sedimentation, Sand Filtration and Chlorination on the Virus of Poliomyelitis. Am J Public Health Nations Health (1942) 3.26
Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet (1995) 3.17
Recovery from chronic fatigue syndrome after treatments given in the PACE trial. Psychol Med (2013) 2.82
Drowning in people with epilepsy: how great is the risk? Neurology (2008) 2.80
P40SDB25, a putative CDK inhibitor, has a role in the M/G1 transition in Saccharomyces cerevisiae. Genes Dev (1994) 2.72
Anaerobic Degradation of Chloroaromatic Compounds in Aquatic Sediments under a Variety of Enrichment Conditions. Appl Environ Microbiol (1989) 2.69
National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet (1990) 2.65
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett (1998) 2.61
Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet (1998) 2.58
Characterization of anaerobic dechlorinating consortia derived from aquatic sediments. Appl Environ Microbiol (1989) 2.57
DNA polymerase II, the probable homolog of mammalian DNA polymerase epsilon, replicates chromosomal DNA in the yeast Saccharomyces cerevisiae. EMBO J (1992) 2.51
Falls in the elderly related to postural imbalance. Br Med J (1977) 2.47
The yeast DNA polymerase I transcript is regulated in both the mitotic cell cycle and in meiosis and is also induced after DNA damage. Nucleic Acids Res (1987) 2.38
Infection of the uterine cervix with Chlamydia trachomatis. J Infect Dis (1978) 2.36
Cloning DPB3, the gene encoding the third subunit of DNA polymerase II of Saccharomyces cerevisiae. Nucleic Acids Res (1991) 2.34
Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun (1989) 2.23
National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet (1990) 2.22
Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry (1999) 2.12
Is cardiac resuscitation worthwhile? A decade of experience. N Engl J Med (1972) 2.07
Aetiology of urinary symptoms in sexually active women. Genitourin Med (1986) 2.03
Integrated hospital and community psychiatric services and use of inpatient beds. BMJ (1989) 2.03
Antiviral agents. 2. Structure-activity relationships of compounds related to 1-adamantanamine. J Med Chem (1971) 1.99
The forkhead protein Fkh2 is a component of the yeast cell cycle transcription factor SFF. EMBO J (2000) 1.95
Cranial cruciate ligament rupture. Pathogenesis, diagnosis, and postoperative rehabilitation. Vet Clin North Am Small Anim Pract (1993) 1.89
Results of cardiac resuscitation in 552 patients. Am J Cardiol (1967) 1.88
Expression of the yeast DNA primase gene, PRI1, is regulated within the mitotic cell cycle and in meiosis. Mol Gen Genet (1990) 1.85
Expanded profile of the SHAFT syndrome. J Hand Surg Am (1998) 1.84
Overlapping and distinct roles of the duplicated yeast transcription factors Ace2p and Swi5p. Mol Microbiol (2001) 1.82
Order of function of the budding-yeast mitotic exit-network proteins Tem1, Cdc15, Mob1, Dbf2, and Cdc5. Curr Biol (2001) 1.76
Oral contraceptives, depression, and libido. Br Med J (1971) 1.74
The Skn7 response regulator of Saccharomyces cerevisiae interacts with Hsf1 in vivo and is required for the induction of heat shock genes by oxidative stress. Mol Biol Cell (2000) 1.69
Stable carbon isotope analysis of nucleic acids to trace sources of dissolved substrates used by estuarine bacteria. Appl Environ Microbiol (1990) 1.67
A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain (1982) 1.62
Involvement of apoptosis in ovarian follicular atresia and postovulatory regression. Endocrinology (1991) 1.61
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.60
A Bub2p-dependent spindle checkpoint pathway regulates the Dbf2p kinase in budding yeast. EMBO J (1999) 1.60
The Swi5 transcription factor of Saccharomyces cerevisiae has a role in exit from mitosis through induction of the cdk-inhibitor Sic1 in telophase. Genetics (1997) 1.59
Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. Psychol Med (2005) 1.59
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.57
Rme1, a negative regulator of meiosis, is also a positive activator of G1 cyclin gene expression. EMBO J (1995) 1.56
Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol (2001) 1.56
The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet (1988) 1.53
Depressive symptoms and oral contraceptives. Br Med J (1970) 1.53
Association of the cell cycle transcription factor Mbp1 with the Skn7 response regulator in budding yeast. Mol Biol Cell (1999) 1.53
Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther (1990) 1.50
Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension (1991) 1.48
Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. Int J Epidemiol (2001) 1.48
Chronic lead absorption. Result of poor ventilation in an indoor pistol range. JAMA (1975) 1.48
Evaluation of fibular head transposition, lateral fabellar suture, and conservative treatment of cranial cruciate ligament rupture in large dogs: a retrospective study. J Am Anim Hosp Assoc (1996) 1.48
Self-recording of blood pressure in the management of hypertension. Can Med Assoc J (1978) 1.46
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.46
The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med (1984) 1.46
A new class of synthetic auxin transport inhibitors. Plant Physiol (1976) 1.45
Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci (1991) 1.45
Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet (1996) 1.41
Randomised controlled clinical trial for the use of deracoxib during intense rehabilitation exercises after tibial plateau levelling osteotomy. Vet Comp Orthop Traumatol (2010) 1.38
Influence of race, sex and weight on blood pressure behavior in young adults. Am J Cardiol (1975) 1.38
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost (2008) 1.38
Lest we forget: Early Canadian contributions to the care of children with congenital heart malformations. Can J Cardiol (2001) 1.37
Mandibular fractures in the dog. A retrospective study of 157 cases. Vet Surg (1990) 1.37
The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry (1986) 1.36
An improved assay for DNA ligase reveals temperature-sensitive activity in cdc9 mutants of Saccharomyces cerevisiae. Mol Gen Genet (1985) 1.36
Patient compliance with antihypertensive regimens. Patient Couns Health Educ (1978) 1.31
A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry (1986) 1.27
The description of activities of daily living in five centres in England and Wales. Medical Research Council Cognitive Function and Ageing Study. Age Ageing (1998) 1.25
Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin Pharmacol Ther (1977) 1.25
Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry (1995) 1.24
Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med (1984) 1.24
Compliance with antihypertensive drug therapy. Ann N Y Acad Sci (1978) 1.23
The Bub2-dependent mitotic pathway in yeast acts every cell cycle and regulates cytokinesis. J Cell Sci (2001) 1.21
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem (1996) 1.20